Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Gastroenterology. 2022 Feb 12;162(7):1962–1974.e6. doi: 10.1053/j.gastro.2022.02.016

Figure 4. LPS is a required component in the IBS-D fecal supernatant for mast cell activation and SERT downregulation.

Figure 4.

(A) Intracolonic infusion of FS from IBS-D patients who responded to 4-wk low-FODMAP treatment resulted in increased SERT expression in mouse colon compared to infusion of FS from the same patients before low-FODMAP. Results are expressed as individual values, Wilcoxon signed-rank test, n = 8 with duplicated measurements. (B) SERT expression in colonic mucosa of mice treated with HC FS, IBS-D FS, pretreatment with LPS-RS (30-min intracolonic infusion) followed by IBS-D FS or IBS-D FS pretreated with endotoxin removal. Results are expressed as mean ± SEM, one-way ANOVA, n = 4–7 in each group. (C) SERT expression in murine colonic organoids co-cultured with mast cells, treated with PBS, IBS-D FS, or IBS-D FS pretreated with endotoxin removal. Results are expressed as mean ± SEM, one-way ANOVA, n = 6 in each group. (D) RT–PCR of COX-2 in cultured bone marrow–derived mast cells treated with LPS for 4 h (0, 3, 10 μg/mL). Results are expressed as mean ± SEM. one-way ANOVA, n = 6–8 in each group. (E) Release of PGE2 from mast cells treated with LPS for 4 h (0, 3, 10 μg/mL). Results are expressed as mean ± SEM. one-way ANOVA, n = 5–6 in each group.